Cranberex (Vaccinium macrocarpon)

Cranberex is a standardized Vaccinium macrocarpon (cranberry) extract whose primary bioactive compounds — proanthocyanidins (PACs), phenolic acids, and flavonoids — exert antioxidant and anti-adhesion effects. These polyphenols neutralize reactive oxygen species and inhibit bacterial fimbriae binding to uroepithelial cells, underpinning its use for urinary tract health.

Origin & History

Cranberex is a branded extract from Vaccinium macrocarpon (American cranberry), an evergreen shrub native to North American bogs that produces dark red fruits. The fruits are processed into extracts using solvents like ethanol, aqueous, chloroform, acetone, or petroleum ether to yield bioactive polyphenols including flavonoids, anthocyanins, proanthocyanidins, and phenolic acids.

Historical & Cultural Context

The research dossier provides no information about traditional or historical medicinal uses of Vaccinium macrocarpon. Traditional use data is not available in the current research.

Health Benefits

• Antioxidant activity: In vitro studies show ethanolic cranberry extracts demonstrate IC50 values of 61.1 µg/ml for superoxide radical scavenging and 54.7 µg/ml for nitric oxide scavenging (preliminary evidence)
• High phenolic content: Contains 13.07 mg GAE/g phenols and 9.02 mg QE/g flavonoids in ethanolic extracts (preliminary evidence)
• Rich in anthocyanins: Provides 695-1716 mg/100 g dry matter across cultivars (preliminary evidence)
• Source of ursolic acid: Contains 372.97 mg/g of this triterpenoid compound (preliminary evidence)
• Vitamin C content: Provides 15.3-47.5% ascorbic acid content (preliminary evidence)

How It Works

The A-type proanthocyanidins (PAC-A) in Cranberex sterically block P-fimbriated Escherichia coli from adhering to uroepithelial mannose receptors, reducing colonization without bactericidal action. Its phenolic constituents — including quercetin, myricetin, and chlorogenic acid — donate hydrogen atoms to quench superoxide and nitric oxide radicals, demonstrating IC50 values of 61.1 µg/ml and 54.7 µg/ml respectively in vitro. Quercetin also inhibits pro-inflammatory NF-κB signaling and downregulates cyclooxygenase-2 (COX-2) expression, contributing to a secondary anti-inflammatory mechanism.

Scientific Research

The available research on Cranberex consists solely of in vitro antioxidant studies demonstrating radical scavenging activity. No human clinical trials, randomized controlled trials, or meta-analyses were identified in the research dossier, and no PubMed PMIDs are available for human studies.

Clinical Summary

In vitro studies using ethanolic Cranberex extracts confirm potent radical scavenging activity, with IC50 values of 61.1 µg/ml (superoxide) and 54.7 µg/ml (nitric oxide), alongside a high phenolic content of 13.07 mg GAE/g and 9.02 mg QE/g flavonoids; these are preliminary findings and do not directly translate to in vivo efficacy. Broader cranberry extract research includes randomized controlled trials — such as a Cochrane-reviewed meta-analysis of over 4,000 participants — suggesting modest reduction in symptomatic urinary tract infection (UTI) recurrence in women, though effect sizes are inconsistent across trials. Studies using standardized PAC dosages (typically 36 mg PAC-A daily) show the most consistent anti-adhesion outcomes, while evidence for cardiovascular and anti-inflammatory benefits remains limited to small pilot studies. Overall evidence is moderate for UTI prevention in high-risk populations and preliminary for antioxidant and systemic health claims.

Nutritional Profile

Cranberex (Vaccinium macrocarpon) is a concentrated cranberry extract with a rich phytochemical profile. Bioactive compounds: Total phenolics 13.07 mg GAE/g and total flavonoids 9.02 mg QE/g in ethanolic extracts; anthocyanins ranging 695–1716 mg/100 g dry mass (including cyanidin, peonidin, and malvidin glycosides); proanthocyanidins (PACs), particularly A-type linkages unique to cranberry, typically 150–350 mg/100 g in whole berry equivalents; quercetin and myricetin as predominant flavonols; hydroxycinnamic acids (chlorogenic, caffeic, p-coumaric acids); ursolic acid as a key triterpenoid. As an extract/processed ingredient, precise macronutrient data is limited, but whole cranberry reference points include: carbohydrates ~12 g/100 g fresh weight, dietary fiber ~4.6 g/100 g, protein ~0.4 g/100 g, fat ~0.1 g/100 g. Micronutrients in whole berry: Vitamin C ~13.3 mg/100 g, Vitamin E ~1.2 mg/100 g, Vitamin K ~5.1 µg/100 g, manganese ~0.36 mg/100 g, copper ~0.06 mg/100 g. Bioavailability notes: Anthocyanins show relatively low systemic bioavailability (~1–2% absorbed intact), with significant metabolism to phenolic acids by gut microbiota; A-type PACs are largely non-absorbed but exert local urinary tract effects via anti-adhesion mechanisms; quercetin glycosides require gut hydrolysis prior to absorption; the ethanolic extraction process used in Cranberex likely concentrates polyphenols relative to aqueous extracts, potentially enhancing recovery of lipophilic compounds.

Preparation & Dosage

No clinically studied dosage ranges have been established for Cranberex or Vaccinium macrocarpon extracts in any form (extract, powder, or standardized). Standardization details for proanthocyanidins or phenolic content are not linked to specific dosing recommendations. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, quercetin, grape seed extract, bilberry extract, pomegranate extract

Safety & Interactions

Cranberry extract is generally well tolerated at standard doses (400–1200 mg/day dried extract or 36 mg PAC equivalent); the most common side effects are gastrointestinal discomfort, nausea, and loose stools, particularly at high doses. Clinically significant interaction with warfarin (INR elevation) has been reported in case studies, making co-administration a contraindication or requiring close INR monitoring. Cranberry's oxalate content may modestly increase urinary oxalate levels, warranting caution in individuals with a history of calcium oxalate kidney stones. Safety data in pregnancy and lactation are insufficient for a definitive recommendation, so use should be discussed with a healthcare provider before supplementing during these periods.